NYMOX Pharmaceutical Corporation

Nasdaq: NYMX

"… working to introduce a new, safe, efficacious and long-lasting therapy to the millions of men suffering from an enlarged prostate gland (BPH)".



FORWARD LOOKING STATEMENTS:

Certain information contained in this presentation may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Such forward-looking statements or information include, without limitation, statements or information about the results of our studies, anticipated financial performance, business prospects, strategies, regulatory developments and market acceptance. Forward-looking statements and information can be identified by the use of words such as “anticipated”, “expected”, “estimated” or similar words and phrases that state or indicate that certain actions, events or results “may”, “could”, “might” or “will” be taken, occur or be achieved.

Such statements or information reflect Nymox Pharmaceutical Corporation’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions including, without limitation, the actual results of our studies, our actual financial performance, our ability to carry out our research and development plans, including our ability to obtain or maintain regulatory approvals, competition and market demand for any future product and our ability to obtain financing.

Forward-looking statements and information are necessarily based upon estimates and assumptions that, while considered reasonable by management, are inherently subject to significant risk and uncertainty. Many factors could cause our actual results, performance or achievements to be materially different from those that may be expressed or implied by such forward-looking statements or information. Such factors and corresponding risks and uncertainties are detailed in Nymox Pharmaceutical Corporation’s SEC filings. Should one or more of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements or information prove incorrect, actual results may vary materially from those described herein. Except as required by law, Nymox Pharmaceutical Corporation expressly disclaims any intention or obligation to update or revise any forward-looking statements and information. All forward-looking statements and information are expressly qualified in their entirety by the foregoing cautionary statements.

TODAY'S PRESENTATION OUTLINE:

1) THE PROMISE AND THE OPPORTUNITY, WHO WE ARE

2) RECENT HISTORY OF THE COMPANY

3) CLINICAL DATA HIGHLIGHTS

4) THE FUTURE

NYMOX' MISSION

NYMOX IS DEVELOPING A NOVEL, PROPRIETARY TREATMENT FOR A CHRONIC CONDITION THAT NEGATIVELY IMPACTS THE LIVES OF MOST AGEING MEN ABOVE 60 AROUND THE WORLD:

BENIGN PROSTATIC HYPERPLASIA (BPH)*)

*) Worldwide incidence of >100M men today.

Main Assets


Fexapotide Triflutate
(NX-1207)
Benign Prostate Hyperplasia
BPH
Early Stage Prostate
Cancer
Status
Status
• Phase III Clinical Program in the U.S. Completed
• Successful pre-NDA meeting with the FDA
• Regulatory filings with FDA & EMA in preparation
• Successful production scale-up achieved.
> Successful Phase II Completed
> Registrational study in planning.

THE NYMOX TREATMENT
for BPH

Drug Name: *Fexapotide Triflutate (FT)*

(formerly NX-1207)

Transrectal Injection Into the Prostate



Enlarged Prostate



Two painless injections (few min procedure)
> Intra-rectally, under ultrasound guidance.
> No anesthetics / sedation required
> Drug injected into the «transition zone».



Improved Prostate

DRUG MECHANISM:

> Induces apoptosis (natural cell death).
> Cells die naturally and lessens pressure on the urethra.

*) schematic illustration.

NYMOX

Status of Clinical Program in BPH:

- Two large Phase III Trials in the United States: COMPLETED
- More than 70 clinical sites across the U.S. involved.
- More than 970 men treated in the Phase III Program.
- Up to five-year clinical follow-up on study-participants.

Nymox Comments:

- ✓ No uncertainty about future clinical study results.
- ✓ Treatment effect is now well established and documented.

Demonstrated Long-term Clinical Benefits:

- Long-lasting BPH Symptom Relief (>7 years), based on one treatment. Treatment can be safely repeated with additional therapeutic benefit.
- FT Treatment provides 2-3x symptom relief effect seen with oral medication, which has side-effects.
- Excellent Safety: No drug related adverse side-effects. Improved sexual function.
- Statistically significantly reduced incidence of prostate cancer over the long-term.
- Statistically significant reduced need for surgical intervention long-term.
- All alternative treatment options (oral medication, minimally invasive procedures and surgery) are all associated with clinically meaningful adverse side-effect profiles.

Efficacy Results Summary From U.S. Phase III Study

Change From Baseline = Benefit to Patient

- **5.7 points improvement** at 3.6 years after single injection
- **6.6 points improvement** in first-line patients (**treatment naïve**) at 3.6 years after single injection.
- **> 8 points** improvement after 2 injections.

Comment:

Patients have substantial symptom improvement as soon as 10 days after treatment. Long-term a second injection confers on average over 8 points IPSS improvement from baseline.

Sounds *“too good to be true?”*

Fexapotide Triflutate Data Has Been Scrutinized

- Nymox Phase III clinical trial results have been presented multiple times by leading U.S. urologists at regional and national AUA meetings in 2017 and 2018.

- Study results published and discussed in:
  - **World Journal of Urology** (January 2018)
  - **Therapeutic Advances in Urology** (January 2019)

World Journal of Urology
https://doi.org/10.1007/s00345-018-2185-y

ORIGINAL ARTICLE

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

Neal Shore[1] · Ronald Tutrone[2] · Mitchell Efros[3] · Mohamed Bidair[4] · Barton Wachs[5] · Susan Kalota[6] · Sheldon Freedman[7] · James Bailen[8] · Richard Levin[9] · Stephen Richardson[10] · Jed Kaminetsky[11] · Jeffrey Snyder[12] · Barry Shepard[13] · Kenneth Goldberg[14] · Alan Hay[15] · Steven Gange[16] · Ivan Grunberger[17]

Nymox: Development History

- Phase 3 study results showed the 12 months post treatment primary endpoint failed in November 2014 and therefore longer-term follow-up study was required to determine drug efficacy.

- The company performed additional long-term extension study protocols and outcome analysis up to 6 years post-treatment.

- In 2015, the company announced that the long-term follow up data met the primary endpoint long- term and there was statistically significant treatment benefit in FT treated patients versus placebo.

Multiple Long-term Treatment Benefits of FT:

- **Cancer Benefit** (June 2016): Company reported significantly lower incidence of prostate cancer in FT treated men in its Phase III Study Program for BPH. Median follow up time: 5 years. FT Cancer Incidence: 1.3%, Placebo: 6.3%.
- **Less Need for Surgery** (August 2016): For patients in the Phase III BPH trial who initially received placebo and subsequently crossed over to either FT or conventional therapies, there was an 82-95% reduction in the eventual need for surgery in the FT treated group.
- **Repeat FT Tre**atment (October 2016) is safe and induces long-term BPH symptom relief up to 6 years after initial treatment.
- Superior results (symptom relief) both short- and long-term in **treatment naïve men** (November 2016).
- **Improved sexual function** in FT treated group (May 2017)

Strong Clinical Data has allowed Company to Recover

- Access to significant capital in spring 2018; USD 18M.
- Adequately financed to complete regulatory process.
- Clean, straight equity at a 10% discount to the market.
- Strong, supportive shareholders that invest in our BP.
- Insiders participated in the financing.

- New capital has allowed company to significantly upgrade and expand regulatory advisory teams, both in the United States and Europe.

- Successful pre-NDA meeting with the FDA (January 2018).
- Successful CMC Meeting with the FDA (April 2019)

Fexapotide Therapy Summary / Profile:

At least twice as efficacious as currently used oral therapies.

No side-effects – currently prescribed therapies have significant side-effects profiles.

Durable treatment effect. Easy for patient to comply with therapy.

Cancer inhibitory properties.

Quick, painless procedure in the doctor's office.

Improved sexual function, no incontinence and no effect on testosterone levels. Maintained quality of life.

Corporate Summary

- Block-buster market opportunity; >100M potential patients WW.
- No competition. Very attractive COGS.
- Potentially Disease Modifying Treatment:
  - Almost twice as efficacious as current non-surgical treatment modalities
  - Demonstrated *reduced incidence of surgery* in treated patients.
  - Demonstrated *reduced incidence of urinary retention* in treated patients.
  - Demonstrated *reduced long-term incidence in prostate can*cer in treated patients.
  - *No side-effects.* Treatment is extremely safe.
  - *Improved sexual function;* no treatment induced damage to nerves.
  - Treatment can be *safely repeated*.
- Company owns 100% commercial rights worldwide.
- Strong IP: Several new, recently issued patents.

NYMOX

Corporate Summary

- Well financed (Q1-2019: $11.3M) through to to completion of regulatory process.
- Shares outstanding: approx. 70M.
- Clean capital structure, no debt.
- No warrant overhang.
- No larger lingering expenses. All trials have been paid for. Only regulatory.

What does Nymox Represent:

Significant Opportunity

Risk / Reward

Current Market Cap:
<$120M

Blockbuster sales potential.

... many significant milestones in next year



Upcoming Corporate Milestones Next 12-18 Months.

- File for Regulatory Approval in the United States and Europe.
- Clinical advancement of Fexapotide Triflutate for early stage prostate cancer.
- Continue to augment and enhance management team.
- Prepare for commercialization.
- Potential Commercial Partnerships.
- Additional Clinical Publications.
- Obtain regulatory clearance for FT in BPH.

Pharmaceutical Corporation

Nasdaq: NYMX

Thank you for your attention!

Erik Danielsen
CFO
EDanielsen@Nymox.com
Cell: +41 (76) 335.4402